Japan Approves the World's First Treatment Made With Reprogrammed Human Cells Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology. Human iPS cell colony established from fibroblasts. Its actual width is approximately 0.5 mm. On March 6, Japan's Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells .

Researchers have used machine learning to predict the conditions needed for stem cells to develop a certain way, which could be used to grow 3D organ models. Researchers have used a computational model to learn how to manipulate stem cell arrangement, including those that may eventually be useful in generating personalised organs. According to the team, their discovery could be used to develop model organs grown from a patient's own cells, which could'revolutionise' how diseases are treated by increasing disease understanding or testing drugs. The study was conducted by a team from Gladstone Institutes, in collaboration with Boston University, both US. Induced pluripotent stem (iPS) cells, similar to the stem cells found in an embryo, have the potential to become nearly every type of cell in the body.